Your browser doesn't support javascript.
loading
Stent Expansion Indexes to Predict Clinical Outcomes: An IVUS Substudy From ADAPT-DES.
Fujimura, Tatsuhiro; Matsumura, Mitsuaki; Witzenbichler, Bernhard; Metzger, D Christopher; Rinaldi, Michael J; Duffy, Peter L; Weisz, Giora; Stuckey, Thomas D; Ali, Ziad A; Zhou, Zhipeng; Mintz, Gary S; Stone, Gregg W; Maehara, Akiko.
Afiliación
  • Fujimura T; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Matsumura M; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Witzenbichler B; Department of Cardiology and Pneumology, Helios Amper-Klinikum, Dachau, Germany.
  • Metzger DC; Ballad Health CVA Heart Institute, Kingsport, Tennessee, USA.
  • Rinaldi MJ; Sanger Heart & Vascular Institute/Atrium Health, Charlotte, North Carolina, USA.
  • Duffy PL; Appalachian Regional Healthcare System, Boone, North Carolina, USA.
  • Weisz G; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Stuckey TD; LeBauer-Brodie Center for Cardiovascular Research and Education/Cone Health, Greensboro, North Carolina, USA.
  • Ali ZA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA; St. Francis Hospital, Roslyn, New York, USA. Electronic address: https://twitter.com/ziadalinyc.
  • Zhou Z; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Mintz GS; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Stone GW; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: https://twitter.com/GreggWStone.
  • Maehara A; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA. Electronic address: amaehara@crf.org.
JACC Cardiovasc Interv ; 14(15): 1639-1650, 2021 08 09.
Article en En | MEDLINE | ID: mdl-34353595
ABSTRACT

OBJECTIVES:

The aim of this study was to evaluate various stent expansion indexes to determine the best predictor of clinical outcomes.

BACKGROUND:

Numerous intravascular ultrasound (IVUS) studies have shown minimum stent area (MSA) to be the most powerful predictor of future events.

METHODS:

ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was a prospective, multicenter registry of 8,582 patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents. Native coronary artery lesions treated with IVUS-guided PCI with final analyzable IVUS were included. Ten stent expansion indexes (MSA, MSA/vessel area at MSA site, conventional stent expansion [MSA/average of proximal and distal reference luminal area], minimum stent expansion using Huo-Kassab or linear model accounting for vessel tapering, stent asymmetry [minimum/maximum stent diameter within the entire stent], stent eccentricity [smallest minimum/maximum stent diameter at a single slice within the stent], IVUS-XPL [Impact of intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long Lesions] criteria, ULTIMATE [Intravascular Ultrasound Guided Drug Eluting Stents Implantation in "All-Comers" Coronary Lesions] criteria, and ILUMIEN IV criteria) were evaluated for their associations with lesion-specific 2-year clinically driven target lesion revascularization (TLR) or definite stent thrombosis.

RESULTS:

Overall, 2,140 lesions in 1,831 patients were included; final MSA measured 6.2 ± 2.4 mm2. Among the 10 stent expansion indexes, only MSA/vessel area at the MSA site was independently associated with 2-year clinically driven TLR or definite stent thrombosis (hazard ratio 0.77; 95% confidence interval 0.59-0.99; P = 0.04) after adjusting for morphologic and procedural parameters.

CONCLUSIONS:

In this IVUS-guided PCI cohort with excellent final MSA overall, stent/vessel area at the MSA site, an index of relative stent expansion, was superior to absolute MSA and other expansion indexes in predicting 2-year clinically driven TLR or definite stent thrombosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Intervención Coronaria Percutánea Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: JACC Cardiovasc Interv Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Intervención Coronaria Percutánea Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: JACC Cardiovasc Interv Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos